Inhalation-focused CDMO Bespak has completed its first life cycle assessment on its pressurised metered dose inhaler (pMDI) valve, BK357.
The valve is designed to reduce the carbon footprint of inhaler devices, with the project being conducted to understand the carbon impact of Bespak's materials and manufacturing processes.
This news follows Bespak's prior investments into its clinical and commercial production capacity of pMDIs incorporating its low-GWP propellants, HFA-152a and HFO-1234ze.
The life cycle assessment, according to Bespak, has been independently verified by sustainability experts from Tunley Environmental in line with ISO 14067:2018 standards.
Notably, a verified LCA certification will enable industry partners to leverage insights that support transparency in sustainability reporting and procurement, as well as the transition to net zero.
The LCA will also provide clear direction for future carbon reduction initiatives at Bespak, including emission-saving opportunities in the material and energy stages of the product life cycle.
“The completion of the LCA for our widely used and trusted BK357 pMDI valve demonstrates Bespak’s active commitment to championing sustainability in the supply chain for the benefit of customers, patients and the planet," commented Chris Hirst, CEO of Bespak.
"We are excited to be actively researching solutions for carbon reduction beyond the propellant switch, and are proud to provide credible, independently verified data to back up our environmental claims.”
Benedicta Bakpa, Head of ESG at Bespak, commented: “This important milestone signifies our ongoing commitment to transparency and accountability in driving sustainable operations. As part of our overarching sustainability initiatives, we continue to identify opportunities to reduce our carbon footprint and work towards our near- and long-term net zero targets.”